Health & Pharma
FDA Approves the First DNA-Based Immunotherapy, on a 32-Patient Trial
Inovio's Voceryq is the first plasmid DNA-based immunotherapy cleared in the U.S., winning accelerated approval for a rare airway disease on a 32-patient study. The confirmatory trial is still ahead.
- A Catholic Nonprofit Is Taking Surgery Partners Private
- Hepatitis B's First Functional Cure Reaches the US Market
- AstraZeneca's Ultomiris Cuts IgAN Proteinuria 43%, but the Kidney Proof Is Still Pending
- GSK's New Drug Could Spare Rectal Cancer Patients Surgery
- Spire’s £1.03 Billion Takeover Shifts the Hospital Cost Test to Private Capital
- SEC-FDA Data Pact Tightens the Disclosure Test for Life-Sciences Companies
- Tempus-Personalis Deal Turns Cancer Testing Into an AI Scale Test
- Elevance’s Medicaid Retreat Turns Managed Care Into a Margin Test





































